Literature DB >> 35433949

Efficacy and safety of Chinese medicine combined with balloon dilatation vs. balloon dilatation alone for achalasia patients: a systematic review and meta-analysis.

Junqian Chen1, Xiaoxun Huang2, Yingting Li1, Haomeng Wu1, Shumin Qin1, Huan Zheng1, Jianhua Li1, Haiyan Zhang1, Lijuan Hu1, Shaogang Huang1.   

Abstract

Background: Balloon dilatation is widely used for patients with achalasia; however, the efficacy and safety of Chinese medicine combined with balloon dilatation for achalasia patients is still unclear. Therefore, we conducted a meta-analysis to compare the treatment effectiveness of treatment with Chinese medicine plus balloon dilatation versus balloon dilatation alone for patients with achalasia.
Methods: Randomized controlled trials (RCTs) compared the effectiveness of Chinese medicine plus balloon dilatation with balloon dilatation as examined in studies in the PubMed, Springer, Embase, Wiley-Blackwell, Chinese Journal Full-text Database, and the Cochrane library from their inception up to May 2019. The odds ratios (ORs) and weighted mean differences (WMDs) with corresponding 95% confidence intervals (CIs) were used to calculate categories and continuous outcomes using the random-effects model. The inclusion of studies according to the PICOS (participants, interventions, comparisons, outcomes) criteria, the assessment of risk of bias of included studies adhered to the Cochrane criteria guidelines.
Results: The initial electronic searches produced 378 records, and 10 RCTs that recruited 504 achalasia patients were included in the final quantitative analysis. Except for other potential biases with moderate to high-risk bias of 20-40%, the other six items had a low-risk bias of 80-90%. Overall, we noted that patients who received the Chinese medicine plus balloon dilatation treatment had a greater incidence of improvement at 1 year (OR: 2.20; 95% CI: 1.45-3.33; P<0.001), and 5 years (OR: 1.83; 95% CI: 1.23-2.74; P=0.003), and reduced the risk of gastroesophageal reflux (OR: 0.42; 95% CI: 0.24-0.76; P=0.004) than patients who underwent balloon dilation only. However, patients who received the Chinese medicine plus balloon dilatation treatment did not have a greater risk of perforation (OR: 0.53; 95% CI: 0.24-1.19; P=0.123) compared with patients undergoing balloon dilation. Finally, Chinese medicine plus balloon dilatation was associated with high esophageal sphincter pressure (WMD: 2.01; 95% CI: 1.19-2.84; P<0.001) compared with patients who underwent balloon dilatation only. Conclusions: Chinese medicine plus balloon dilatation had better effects after treatment than balloon dilatation alone for achalasia patients. Given the risk of bias of included studies, the conclusion should be made with cautions. 2022 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Chinese medicine; achalasia; balloon dilatation

Year:  2022        PMID: 35433949      PMCID: PMC9011217          DOI: 10.21037/atm-22-744

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


Introduction

Achalasia is a kind of esophageal motor dysfunction caused by lesions on the primary esophageal nerve and smooth muscles. The main clinical manifestations of achalasia are dysphagia, post-sternal pain, and food reflux (1-3). Research shows that potential reasons for these manifestations are: (I) the damage of the nerve plexus in the esophageal wall, which causes dysfunction of the autonomic nervous system and the sympathetic nervous system; (II) the degeneration of the myenteric plexus caused by a neurotoxic virus; and (III) the lower esophageal sphincter contains vasoactive intestinal peptide that is significantly lower than normal level, leading to an increase of the tension of the esophageal smooth muscle in achalasia (4-6). Balloon dilatation is an endoscopic treatment method for ruptures of the esophageal lower sphincter muscle fibers, which uses inflatable balloon dilatation to reduce tension caused by the rupture (7-9). In doing so, endoscopic balloon dilation may improve the symptoms of achalasia. However, dilatation therapy mainly solves swallowing difficulties, and uncontrolled complications are inevitable. Therefore, additional treatment strategies should be employed to obtain greater benefits and avoid any potential adverse complications. To improve the treatment methods for achalasia, traditional Chinese medicine was used and added to the balloon dilatation method for patients with achalasia (10-12). The traditional Chinese medicine treatment of achalasia is mainly based on regulating qi to open depression, resolving phlegm to disperse knot, promoting blood circulation to remove stasis, nourishing Yin to moisten dryness, and stimulating diaphragm to have an appetite. In light of syndrome differentiation and targeted treatment, the traditional Chinese medicine combined with acupuncture and moxibustion and massage achieved a good effect (13). Several existing studies compared the treatment effectiveness of Chinese medicine plus balloon dilatation vs. balloon dilatation only for patients with achalasia, but the observed results were inconsistent (13,14). Therefore, this study used a quantitative meta-analysis to systematically evaluate the effectiveness of treatment with Chinese medicine plus balloon dilatation compared to balloon dilatation only for achalasia patients. We present the following article in accordance with the PRISMA reporting checklist (available at https://atm.amegroups.com/article/view/10.21037/atm-22-744/rc).

Methods

Data sources, search strategy, and selection criteria

This meta-analysis was planned and performed in accordance with Preferred Reporting Items for Systematic Review and Meta-analysis statement (15). We systematically searched PubMed, Springer, Embase, Wiley-Blackwell, Chinese Journal Full-text Database, and the Cochrane library to identify the studies to compare Chinese medicine plus balloon dilatation with balloon dilatation alone for achalasia patients from their inception up to May 2019. The following search terms were used as medical subject headings and free words: Chinese medicine, balloon dilatation, and achalasia. The hand-searches of reference lists from retrieved studies were also reviewed to select any new eligible study. The literature search and study selection were conducted by two authors, and any disagreement was resolved by group discussion. A study was included if it met the following inclusion criteria: (I) patients: patients diagnosed with achalasia; (II) intervention: Chinese medicine plus balloon dilatation; (III) control: balloon dilatation alone; (IV) outcomes: the study reported at least 1 of following outcome: improvement at 1 year and 5 years, perforation, gastroesophageal reflux, and esophageal sphincter pressure; and (V) study design: the study had to have a randomized controlled trial (RCT). The exclusion criteria were the following: (I) a study with an observational design; (II) patients received other treatment strategies; (III) Control group was not balloon dilatation; and/or (IV) study reported outcomes other than the treatment effectiveness of balloon dilation. If results from a study were published more than once, data from the most recent publication was considered eligible for this study.

Data collection

The two reviewers read the full text and extracted the relevant data of each study into the coding table in Microsoft Excel software. The characteristics extracted in this study included the first author’s name, publication year, year of onset, sample size (Chinese medicine with balloon dilatation/balloon dilatation), mean range of patients, intervention, and control.

Quality assessment

The quality of included studies was assessed according to the Cochrane criteria guidelines (16). The data collection and quality assessment were assessed by two authors, and inconsistencies was resolved by an additional author referring to the original article. The items assessed were as follows: selection bias, selection bias, performance bias, detection bias, attrition bias, reporting bias and other potential sources of bias.

Statistical analysis

The summary odds ratio (OR) and 95% confidence interval (CI) were used to calculate the incidence of improvement of perforation and gastroesophageal reflux at 1 year and 5 years after treatment, while the pooled weighted mean difference (WMD) and 95% CI were used to assess esophageal sphincter pressure after treatment with Chinese medicine plus balloon dilatation and balloon dilatation only. The summary results were calculated using the random-effects model (17,18). Heterogeneity among included studies was assessed using the I-square and Q statistic, and P<0.10 was regarded as significant heterogeneity (19,20). Sensitivity analyses were conducted for investigated outcomes to assess the impact of a single study (21). Subgroup analyses were also conducted to assess improvement in perforation, gastroesophageal reflux, and esophageal sphincter pressure at 1 year and 5 years after treatment based on publication year and the mean age of patients. Moreover, the treatment effects between subgroups were also assessed (22). Analysis of publication bias was conducted by funnel plots, Egger (23), and Begg test results (24). The inspection level for pooled results was 2-sided, and P<0.05 was regarded as statistically significant. All statistical analyses were conducted using RevMan (version 5.3.5, Nordic Cochrane Center, Copenhagen, Denmark) and STATA software (version 10.0; Stata Corporation, College Station, TX, USA).

Results

Search results

An initial electronic search produced 378 records, and 343 were excluded because they were duplicates or were about an irrelevant topic. The remaining 35 studies were retrieved for detailed evaluations, and 25 were excluded because the patients were diagnosed with diseases other than achalasia, the studies did not contain an appropriate control, or the study reported outcomes other than the treatment effectiveness of balloon dilation. Finally, 10 RCTs were selected for final analysis (13,14,25-32). shows a flowchart of the identification, inclusion, and exclusion process.
Figure 1

Flow diagram of the study identification, inclusion, and exclusion.

Flow diagram of the study identification, inclusion, and exclusion.

Characteristics of included studies

lists the first author's name, year of publication, age of onset, sample size (Chinese medicine with balloon dilatation vs. balloon dilatation), age range of patients, and outcome parameters for each study. All included articles were published from 2000 to 2018. The sample size was between 12 and 142 patients. The included studies contained 504 patients with achalasia, including 250 who underwent treatment with Chinese medicine plus balloon dilatation and 254 who underwent treatment with balloon dilatation only. The deviation table in the Review Manager 5.0 tutorial was used to assess the risk of each study by applying the criteria for evaluating design-related deviations. The risk of bias and the details of each article are shown in . Except for other potential biases with moderate to high-risk bias of 20–40%, the other six items had a low-risk bias of 80–90%.
Table 1

Characteristics of the included studies

First authorYearCountryAge range (mean)GroupsNumberYears of onset
Huang (25)1997China49.3±4.6Chinese medicine and balloon dilatation10January 2007 to January 2017
Balloon dilatation9
Ma (26)2004China21.8±3.8Chinese medicine and balloon dilatation6January 2004 to November 2009
Balloon dilatation6
Qin (27)2009China47.7±8.7Chinese medicine and balloon dilatation16November 2011 to September 2015
Balloon dilatation14
Tan (28)2012China42.5±11.3Chinese medicine and balloon dilatation11August 2013 to February 2014
Balloon dilatation12
Tao (29)2003China35.4±13.1Chinese medicine and balloon dilatation10December 2000 to December 2002
Balloon dilatation10
Wei (13)2017China35.3±11.3Chinese medicine and balloon dilatation12January 2001 to December 2003
Balloon dilatation10
Yu (14)2016China46.8±2.3Chinese medicine and balloon dilatation38January 2012 to August 2015
Balloon dilatation42
Zhang (30)2001China32.8±8.2Chinese medicine and balloon dilatation72January 2004 to June 2010
Balloon dilatation70
Zhao (31)2018China44.1±7.9Chinese medicine and balloon dilatation34October 1989 to December 2006
Balloon dilatation42
Zhou (32)2018China47.8±6.3Chinese medicine and balloon dilatation41October 2004 to October 2016
Balloon dilatation39
Figure 2

Quality assessment of the included studies. (A) Risk of bias graph; (B) summary risk of bias. “+”, low risk of bias; “?”, unclear risk of bias; “-”, high risk of bias.

Quality assessment of the included studies. (A) Risk of bias graph; (B) summary risk of bias. “+”, low risk of bias; “?”, unclear risk of bias; “-”, high risk of bias.

Improvement at 1 year after treatment

After pooling all included studies, we noted that treatment with Chinese medicine plus balloon dilatation was associated with an increased incidence of improvement at 1 year (OR: 2.20; 95% CI: 1.45–3.33; P<0.001; ), and no evidence of heterogeneity was detected. The conclusions of subgroup analyses in all subsets were consistent with the overall analysis and reported a significantly high incidence of improvement at 1 year in patients who received Chinese medicine plus balloon dilatation treatment (). The results of sensitivity analysis for all indicators are shown in the Figure S1. Sensitivity analysis for improvement at 1 year indicated that this pooled conclusion was stable because the result was not altered by excluding any particular trial (Figure S1A). The funnel plots of publication bias for all indicators are shown in the Figure S2. No significant publication bias for improvement at 1 year was detected (P value for Egger: 0.442; P value for Begg: 0.721; Figure S2A).
Figure 3

The effect of Chinese medicine plus balloon dilatation vs. balloon dilatation alone on the incidence of improvement at 1 year (13,14,25-32). CI, confidence interval.

Table 2

Subgroup analyses for investigated outcomes

OutcomesGroupNumber of studiesOR/WMD and 95% CIP valueHeterogeneity (%)/P valueP value between subgroups
Improvement at 1 yearPublication year0.865
   Before 201052.30 (1.17–4.51)0.0150.0/0.576
   2010 or after52.14 (1.26–3.62)0.0050.0/0.811
Mean age (years)0.793
   ≥40.062.12 (1.28–3.50)0.0030.0/0.901
   <40.042.39 (1.14–5.00)0.0210.0/0.417
Improvement at 5 yearsPublication year0.969
   Before 201051.85 (0.98–3.50)0.0590.0/0.784
   2010 or after51.82 (1.08–3.06)0.0240.0/0.821
Mean age (years)0.915
   ≥40.061.80 (1.09–2.97)0.0210.0/0.871
   <40.041.89 (0.96–3.73)0.06700/0.701
PerforationPublication year0.704
   Before 201040.46 (0.15–1.40)0.1700.0/0.965
   2010 or after40.62 (0.20–1.98)0.4230.0/0.997
Mean age (years)0.865
   ≥40.050.50 (0.16–1.51)0.2160.0/0.987
   <40.030.57 (0.18–1.84)0.3480.0/0.954
Gastroesophageal refluxPublication year0.643
   Before 201050.50 (0.20–1.22)0.1270.0/0.715
   2010 or after50.37 (0.17–0.81)0.0120.0/0.795
Mean age (years)0.811
   ≥40.060.40 (0.19–0.83)0.0150.0/0.853
   <40.040.47 (0.18–1.20)0.1130.0/0.578
Esophageal sphincter pressurePublication year0.095
   Before 201051.11 (−0.23 to 2.46)0.1030.0/0.777
   2010 or after52.56 (1.51 to 3.61)<0.0010./0.687
Mean age (years)0.338
   ≥40.062.33 (1.28 to 3.37)<0.0010.0/0.923
   <40.041.57 (−0.19 to 3.32)0.08033.3/0.212

OR, odds ratios; WMD, weighted mean differences; CI: confidence interval.

The effect of Chinese medicine plus balloon dilatation vs. balloon dilatation alone on the incidence of improvement at 1 year (13,14,25-32). CI, confidence interval. OR, odds ratios; WMD, weighted mean differences; CI: confidence interval.

Improvement at 5 years after treatment

After pooling all included studies, results showed that patients who received the Chinese medicine plus balloon dilatation treatment had a significantly increased incidence of improvement at 5 years after treatment than those who received balloon dilatation only (OR: 1.83; 95% CI: 1.23–2.74; P=0.003; ), and no evidence of heterogeneity was observed. Sensitivity analysis indicated that the pooled conclusion for improvement at 5 years was not changed by sequential exclusion of any individual trial (Figure S1B). Subgroup analyses indicated that the significant differences for improvement at 5 years were mainly detected if the pooled studies were published in or after 2010 and if the mean age of patients was greater than 40.0 years (). No significant publication bias was detected (P value for Egger: 0.305; P value for Begg: 0.721; Figure S2B).
Figure 4

The effect of Chinese medicine plus balloon dilatation vs. balloon dilatation alone on the incidence of improvement at 5 years (13,14,25-32). CI, confidence interval.

The effect of Chinese medicine plus balloon dilatation vs. balloon dilatation alone on the incidence of improvement at 5 years (13,14,25-32). CI, confidence interval.

Perforation

After pooling all included studies, results showed there was no significant difference in the risk of perforation between patients treated with Chinese medicine plus balloon dilatation and those treated with balloon dilatation alone (OR: 0.53; 95% CI: 0.24–1.19; P=0.123; ), and no evidence of heterogeneity was observed. Sensitivity analysis was conducted, and this conclusion was not altered after sequentially excluding individual studies (Figure S1C). Subgroup analyses indicated that there were no significant differences between patients treated with Chinese medicine plus balloon dilatation and patients treated with balloon dilatation alone for the risk of perforation in all subsets (). Finally, no significant publication bias was observed (P value for Egger: 0.189; P value for Begg: 0.174; Figure S2C).
Figure 5

The effect of Chinese medicine plus balloon dilatation vs. balloon dilatation alone on the risk of perforation (13,14,25,27,29-32). CI, confidence interval.

The effect of Chinese medicine plus balloon dilatation vs. balloon dilatation alone on the risk of perforation (13,14,25,27,29-32). CI, confidence interval.

Gastroesophageal Reflux

After pooling all included studies, we noted that Chinese medicine plus balloon dilatation treatment was associated with a reduced risk of gastroesophageal reflux compared with balloon dilatation alone (OR: 0.42; 95% CI: 0.24–0.76; P=0.004; ), and no evidence of heterogeneity was observed. The pooled conclusion was stable and did not change by excluding any specific trial (Figure S1D). Subgroup analyses indicated that the significant differences in the risk of gastroesophageal reflux for patients who were treated with Chinese medicine plus balloon dilatation compared with patients treated with balloon dilatation alone were mainly observed if the pooled studies were published in or after 2010 and if the mean age of patients was greater than 40.0 years (). No significant publication bias for gastroesophageal reflux was detected (P value for Egger: 0.166; P value for Begg: 0.371; Figure S2D).
Figure 6

The effect of Chinese medicine plus balloon dilatation vs. balloon dilatation alone on the risk of gastroesophageal reflux (13,14,25-32). CI, confidence interval.

The effect of Chinese medicine plus balloon dilatation vs. balloon dilatation alone on the risk of gastroesophageal reflux (13,14,25-32). CI, confidence interval.

Esophageal sphincter pressure

After pooling all included studies, results showed that patients who were treated with Chinese medicine plus balloon dilatation had significantly increased esophageal sphincter pressure as compared with patients treated with balloon dilatation alone (WMD: 2.01; 95% CI: 1.19–2.84; P<0.001; ), and no evidence of heterogeneity among included trials. The results of sensitivity analysis indicated that the pooled result was stable after excluding any particular study (Figure S1E). Subgroup analyses indicated that these significant differences were mainly detected if the pooled studies were published in or after 2010 and if the mean age of patients was greater than 40.0 years (). There was no significant publication bias detected (P value for Egger: 0.745; P value for Begg: 0.858; Figure S2E).
Figure 7

The effect of Chinese medicine plus balloon dilatation vs. balloon dilatation alone on esophageal sphincter pressure (13,14,25-32). CI, confidence interval.

The effect of Chinese medicine plus balloon dilatation vs. balloon dilatation alone on esophageal sphincter pressure (13,14,25-32). CI, confidence interval.

Discussion

Cardiac achalasia presents as cardia spasm, esophageal peristalsis, and megaesophagus because it causes motor dysfunction of esophageal nerves and muscles, high pressure in the lower esophageal sphincter, and weakens the relaxation response when swallowing (33-35). All of this can cause flaccidity and prevent food from passing smoothly. This subsequently result in the esophageal tension and peristalsis. Therefore, effective treatment strategies should be employed for patients with achalasia. This comprehensive study reviewed existing studies that together recruited 504 achalasia patients from 10 RCTs across a wide range of patient characteristics. The results of this study indicated that patients treated with Chinese medicine plus balloon dilatation had superior outcomes in terms of improvement at 1 year and 5 years, gastroesophageal reflux, and esophageal sphincter pressure than patients treated with balloon dilatation alone. There was no significant difference between these groups for the risk of perforation. The studies included in the meta-analysis illustrated several techniques for balloon dilatation, including using a guide wire, an endoscopic biopsy channel, and the anterior part of the endoscope body (36-38). During balloon dilation, the balloon could be inserted directly through the endoscopic biopsy hole of the large foramen and could be accurately located and observed during the operation. Balloon dilatation could immediately relieve dysphagia of patients. Previous studies added traditional Chinese medicine to the balloon dilation technique, including balanced acupuncture and chiropractic therapy to balloon dilatation (39-41). However, whether these have additional benefits remains controversial. The results of this meta-analysis showed that the improvement of symptoms at 1 year and 5 years between patients treated with Chinese medicine plus balloon dilatation and those treated with balloon dilatation alone were statistically significant. This suggests that treatment with Chinese medicine plus balloon dilatation was superior to treatment with balloon dilatation only for patients with achalasia. This result is coincident with Tan’s research which showed that the clinical efficacy and esophageal function was better in patients treated with Chinese medicine plus balloon dilatation was better than those treated with only balloon dilatation (42,43). Moreover, we noted that Chinese medicine plus balloon dilatation was associated with a lower risk of gastroesophageal reflux, but the risk of perforation between groups was not statistically significant. Although the significant reduction of the risk of gastroesophageal reflux in patients treated with Chinese medicine plus balloon dilatation was not present in most included studies, the study conducted by Zhou et al. (32) reported a similar result. This could be because the Zhou et al. (32) study reported a high incidence of gastroesophageal reflux, therefore the significant difference was easier to observe. Moreover, the risk of perforation between groups was not detected in all studies, but this may have occurred because of the low incidence of perforation in the included studies. This study has the following limitations: (I) all included studies were conducted in China, which restricted the recommendations of the results of this study; (II) most patient characteristic were not available, which prevented a more detailed analysis; (III) many different types of traditional Chinese medicines could bias the treatment effectiveness, which needs further verification; and (IV) the results of this study were based on published articles, and unpublished data was not available, which might produce overestimation of results. In conclusion, this meta-analysis found that achalasia patients treated with Chinese medicine plus balloon dilatation benefited 1 year and 5 years after treatment and had greater improvements in gastroesophageal reflux and esophageal sphincter pressure than those patients who received balloon dilatation alone. However, no significant differences for the risk of perforation between patients treated with Chinese medicine plus balloon dilatation and balloon dilatation alone were observed. These results need to be verified with further large-scale RCTs. The article’s supplementary files as
  30 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Esophageal Perforation After Pneumatic Dilation for Achalasia: Successful Closure With an Over-the-Scope Clip.

Authors:  Madhusudhan R Sanaka; Siva Raja; Prashanthi N Thota
Journal:  J Clin Gastroenterol       Date:  2016-03       Impact factor: 3.062

Review 3.  Primary cricopharyngeal achalasia in a newborn treated by balloon dilatation: a case report and review of the literature.

Authors:  Omer Erdeve; Meltem Kologlu; Belma Saygili; Begum Atasay; Saadet Arsan
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2006-09-15       Impact factor: 1.675

4.  Response to Elias and Castell.

Authors:  Joel E Richter; John Jacobs; Ambuj Kumar
Journal:  Am J Gastroenterol       Date:  2016-09       Impact factor: 10.864

5.  Laparoscopic approach to esophageal perforation secondary to pneumatic dilation for achalasia.

Authors:  Andrés Sánchez-Pernaute; Elia Pérez Aguirre; Pablo Talavera; Luis Díez Valladares; Julio Pérez de la Serna; Concepción Sevilla Mantilla; Antonio Ruiz de León; Antonio Torres
Journal:  Surg Endosc       Date:  2008-09-24       Impact factor: 4.584

6.  Efficacy of Rigiflex balloon dilatation in 12 children with achalasia: a 6-month prospective study showing weight gain and symptomatic improvement.

Authors:  A A Khan; S Waqar H Shah; Altaf Alam; A K Butt; F Shafqat
Journal:  Dis Esophagus       Date:  2002       Impact factor: 3.429

7.  Comparison of peroral endoscopic myotomy and endoscopic balloon dilation for primary treatment of pediatric achalasia.

Authors:  Yuyong Tan; Hongyi Zhu; Chenjie Li; Yi Chu; Jirong Huo; Deliang Liu
Journal:  J Pediatr Surg       Date:  2016-06-16       Impact factor: 2.545

8.  Endoscopic pneumatic balloon dilation in primary achalasia: predictive factors, complications, and long-term follow-up.

Authors:  J A Tuset; M Luján; J M Huguet; P Canelles; E Medina
Journal:  Dis Esophagus       Date:  2008-11-19       Impact factor: 3.429

9.  Pneumatic dilation versus laparoscopic Heller's myotomy in the treatment of achalasia: systematic review and meta-analysis based on randomized controlled trials.

Authors:  P Bonifácio; D T H de Moura; W M Bernardo; E T H de Moura; G F A Farias; A C M Neto; M Lordello; N Korkischko; R Sallum; E G H de Moura
Journal:  Dis Esophagus       Date:  2019-02-01       Impact factor: 3.429

10.  Pneumatic balloon dilation therapy is as effective as esophagomyotomy for achalasia.

Authors:  Mohammad Hassan Emami; Mostafa Raisi; Jaleh Amini; Abbas Tabatabai; Mehran Haghighi; Hamid Tavakoli; Mozafar Hashemi; Mehdi Fude; Ziba Farajzadegan; Vahid Goharian
Journal:  Dysphagia       Date:  2008-02-06       Impact factor: 3.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.